Symphogen receives US patent on cancer compound

Monday 7 March 2011

The US Patent and Trademark Office has awarded a patent to the privately-owned Symphogen A/S of Denmark for an oncology compound that is based on a mixture of two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark